Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
[cutaneous mastocytosis]
Systemic
mastocytosis
(
SM
)
is
typically
suspected
in
patients
with
cutaneous
mastocytosis
(
CM
)
.
In
recent
years
,
the
presence
of
clonal
mast
cells
(
MCs
)
in
a
subset
of
patients
with
systemic
symptoms
associated
with
MC
activation
in
the
absence
of
CM
has
been
reported
and
termed
monoclonal
MC
activation
syndromes
or
clonal
systemic
MC
activation
syndromes
.
In
these
cases
,
bone
marrow
(
BM
)
MC
numbers
are
usually
lower
than
in
SM
with
CM
,
there
are
no
detectable
BM
MC
aggregates
,
and
serum
baseline
tryptase
is
often
<
20
µg
/
l
;
thus
,
diagnosis
of
SM
in
these
patients
should
be
based
on
careful
evaluation
of
other
minor
WHO
criteria
for
SM
in
reference
centers
,
where
highly
sensitive
techniques
for
immunophenotypic
analysis
and
investigation
of
KIT
mutations
on
fluorescence-activated
cell
sorter-purified
BM
MCs
are
routinely
performed
.
The
prevalence
of
hymenoptera
venom
anaphylaxis
(
HVA
)
among
SM
patients
is
higher
than
among
the
normal
population
and
it
has
been
reported
to
be
approximately
5
%
.
In
SM
patients
with
IgE-mediated
HVA
,
venom
immunotherapy
is
safe
and
effective
and
it
should
be
prescribed
lifelong
.
Severe
adverse
reactions
to
hymenoptera
stings
or
venom
immunotherapy
have
been
associated
with
increased
serum
baseline
tryptase
;
however
,
presence
of
clonal
MC
has
not
been
ruled
out
in
most
reports
and
thus
both
SM
and
clonal
MC
activation
syndrome
might
be
underdiagnosed
in
such
patients
.
In
fact
,
clonal
BM
MC
appears
to
be
a
relevant
risk
factor
for
both
HVA
and
severe
reactions
to
venom
immunotherapy
,
while
the
increase
in
serum
baseline
tryptase
by
itself
should
be
considered
as
a
powerful
surrogate
marker
for
anaphylaxis
.
The
Spanish
Network
on
Mastocytosis
has
developed
a
scoring
system
based
on
patient
gender
,
the
clinical
symptoms
observed
during
anaphylaxis
and
serum
baseline
tryptase
to
predict
for
the
presence
of
both
MC
clonality
and
SM
among
individuals
who
suffer
from
anaphylaxis
.
Diseases
Validation
Diseases presenting
"termed monoclonal mc activation syndromes or clonal systemic mc activation syndromes"
symptom
cutaneous mastocytosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom